Level Bio (LEVBIO) Q4 2025 earnings summary

Executive summary

• Achieved 29% year-over-year revenue growth to 32,361 KSEK for 2025, with Q4 revenue up 26% to 9,422 KSEK compared to the same quarter last year.

• Sold subsidiary CyberGene AB to Devyser AB for 12.2 MSEK in early 2026, resulting in a capital gain of 7–8 MSEK and a strategic focus on core distribution business.

• Positive cash flow throughout 2025, with improved operating results and a strengthened balance sheet supporting future expansion.

Financial highlights

• Full-year net sales: 32,361 KSEK (up 29% from 25,096 KSEK in 2024); Q4 net sales: 9,422 KSEK (up 26%).

• Gross margin for 2025 was 53% (down from 54% in 2024); Q4 gross margin at 52% (down from 58%).

• Operating result (EBIT) for 2025: -3,487 KSEK (improved from -8,083 KSEK); Q4 EBIT: -888 KSEK (improved from -1,479 KSEK).

• Net result after tax for 2025: -3,539 KSEK (improved from -7,872 KSEK); Q4 net result: -1,093 KSEK.

• Cash flow for 2025: 1,406 KSEK (up from -2,551 KSEK); cash and cash equivalents at year-end: 2,485 KSEK.

Outlook and guidance

• Focus shifts to Nordic distribution of molecular biology lab products via Techtum Lab after CyberGene divestment.

• Anticipates a ~15% reduction in consolidated revenue and lower gross margin from Q2 2026 due to CyberGene sale.

• Plans for continued expansion in the Nordics, leveraging a strengthened balance sheet and innovative product portfolio.